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ABSTRACT 
Background:  Experimental and epidemiological evidence have suggested that chronic inflammation 
may play a critical role in endometrial carcinogenesis.  
Methods:  To investigate this hypothesis, a two-stage study was carried out to evaluate single 
nucleotide polymorphisms (SNPs) in inflammatory pathway genes in association with endometrial 
cancer risk. In stage 1, 64 candidate pathway genes were identified and 4,542 directly genotyped or 
imputed SNPs were analyzed among 832 endometrial cancer cases and 2,049 controls, using data 
from the Shanghai Endometrial Cancer Genetics Study. Linkage disequilibrium of stage 1 SNPs 
significantly associated with endometrial cancer (P<0.05) indicated that the majority of associations 
could be linked to one of 24 distinct loci. One SNP from each of the 24 loci was then selected for 
follow-up genotyping. Of these, 21 SNPs were successfully designed and genotyped in stage 2, 
which consisted of ten additional studies including 6,604 endometrial cancer cases and 8,511 
controls.  
Results:  Five of the 21 SNPs had significant allelic odds ratios and 95% confidence intervals as 
follows:  FABP1, 0.92 (0.85-0.99); CXCL3, 1.16 (1.05-1.29); IL6, 1.08 (1.00-1.17); MSR1, 0.90 (0.82-
0.98); and MMP9, 0.91 (0.87-0.97). Two of these polymorphisms were independently significant in 
the replication sample (rs352038 in CXCL3 and rs3918249 in MMP9). The association for the MMP9 
polymorphism remained significant after Bonferroni correction and showed a significant association 
with endometrial cancer in both Asian- and European-ancestry samples.  
Conclusions:  These findings lend support to the hypothesis that genetic polymorphisms in genes 
involved in the inflammatory pathway may contribute to genetic susceptibility to endometrial cancer. 
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INTRODUCTION 
Endometrial cancer is the most common gynecological malignancy in developed countries and 
the second most common in the world (1, 2). While relatively uncommon among Chinese women, its 
incidence has been increasing at an alarming rate. Incidence of endometrial cancer among Chinese 
women in urban Shanghai has increased 90% over the last two decades, from 4.0/100,000 in 1987 
(3) to 7.62/100,000 in 2007 (4). Obesity, early age at menarche, late age at menopause, nulliparity, 
and use of estrogen hormone replacement therapy are established risk factors for endometrial cancer 
(5).  
Although the genetics of endometrial cancer are poorly understood, its heritability of 
approximately 0.5 indicates that there is a strong genetic component for disease risk. A number of 
lines of experimental and epidemiological evidence have indicated that inflammation may play an 
important role in the transition from normal endometrium to malignancy. Of the many risk factors 
associated with endometrial cancer, several--including use of unopposed estrogen, anovulation, 
endometriosis, early age at menarche, and late age at menopause--may contribute to a state of 
prolonged exposure to inflammation (6). Such prolonged exposure can result in derangement of 
cellular processes, which could lead to excessive mitosis, the accumulation of DNA damage, and 
thus cancer (7, 8). Given this evidence, we hypothesized that common genetic polymorphisms in 
inflammatory pathway genes may also influence the risk of this disease. 
To investigate this hypothesis, a two-stage study was used to determine if common variants in 
genes involved in the inflammatory response were associated with endometrial cancer risk using the 
resources of the Shanghai Endometrial Cancer Genetics Study and ten additional studies of 
endometrial cancer conducted among women in the US, Australia, Europe, and China.  
 
MATERIALS AND METHODS 
This study involved two stages, as shown in Table 1. Study populations are described below 
and the overall study design and SNP selection procedure are depicted in Figure 1. 
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Study population 
 
Stage 1 was conducted among the participants of the Shanghai Endometrial Cancer Genetics 
Study (SECGS), which included 832 cases from the Shanghai Endometrial Cancer Study (SECS) and 
2,049 controls from the Shanghai Breast Cancer Study (SBCS) and the Shanghai Women’s Health 
Study (SWHS). Details of these studies have been described previously (9). Data for stage 2 included 
6,604 cases and 8,511 controls from a total of 10 studies (Table 1). IRB approval was obtained for all 
of the parent studies from all contributing institutions, and informed consent was obtained from all 
participants. 
 
Candidate SNP selection 
 
The SNP selection scheme is shown in Figure 1. Sixty-four candidate genes involved in 
inflammatory pathways were identified based on literature review and bioinformatics searches. In 
stage 1 a total of 4,542 SNPs with minor allele frequencies of 0.05 or greater were located in RefSeq 
transcripts of these genes or nearby (± 20kb).Genotyping of these SNPs was carried out as part of a 
larger genome-wide association study previously described (9). Only SNPs that passed quality 
control (QC) from the Affymetrix 6.0 array (Affymetrix, Santa Clara, CA, USA) or that could be 
imputed were eligible for selection. SNPs for stage 2 were selected, using data from HapMap, release 
28, after evaluation of linkage disequilibrium between the associated SNPs. From this, it was 
determined that the majority of associations could be linked to one of 24 distinct loci. The SNP with 
the lowest P value from each of the 24 loci was selected for follow-up genotyping in stage 2.  
 
Genotyping, quality control, and imputation  
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Stage 1 genotyping and QC procedures have been described in detail in previous publications 
(9, 10). Briefly, genotyping was performed using the Affymetrix 6.0 array, which includes 906,602 
SNPs. The Birdseed v2 algorithm (http://www.broad.mit.edu/mpg/birdsuite/) was used to call 
genotypes. QC samples from Coriell Cell Repositories (http://ccr.coriell.org/) were included on each 
96-well plate, and the average concordance percentage among QC samples was 99.85%. Female 
sex was confirmed for all samples. Multidimensional scaling analysis of the genotypes with 210 
unrelated HapMap samples indicated that all participants clustered with HapMap Asian samples 
(CHB+JPT). All potential relatives with pairwise identity by descent (IBD) of PI_HAT>0.25 were 
removed. SNPs that failed the Hardy-Weinberg equilibrium test (P<0.0001) and SNPs that had 
significantly different missing genotyping rates for cases and controls (P<0.0001) were excluded. 
After QC was completed, the Hidden Markov Model as implemented in Mach 1.0 was used to impute 
the genotype for variants of interest that were not directly genotyped using Asian genotyping data 
from HapMap for reference genotypes (11).  
In stage 2, 21 of the 24 SNPs selected for replication genotyping as described above, were 
successfully genotyped. Some stage 2 studies (e.g. HAECS and HJECS) genotyped fewer than  21 
SNPs. Only SNPs which met QC criteria similar to that applied for stage 1 were included in the stage 
2 analysis. Imputed genotypes were used for some SNPs in ANECS/NECS, NSECG, and control 
samples derived from the WTCCC when direct genotyping data were not available (12).  
 
Statistical analysis 
 
Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence 
intervals (CIs) for associations between genotypes and endometrial cancer risk in stage 1. Covariates 
adjusted for included age, income, and education. Directly genotyped or imputed information for 
4,542 SNPs was evaluated for associations with endometrial cancer and 614 SNPs showed a 
nominal association with endometrial cancer (P<0.05).  
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Unconditional logistic regression was used to analyze the 21 SNPs selected for stage 2. These 
analyses were adjusted for age only, because a unifying set of common demographic or 
anthropometric covariates was not available across all studies. Using the ORs derived from individual 
studies, a meta-analysis was conducted derive summary statistics (13). An overall Z-statistic and P 
value based on the weighted average of the individual statistics was calculated. The resulting ORs 
and 95CIs are based on the fixed effect model, unless heterogeneity across studies was evident 
(P<0.05 for homogeneity test). In the latter case, ORs, 95 CIs, and P values derived from the random 
effect model are presented. All P values presented are based on two-tailed tests. 
 
RESULTS 
Stage 1, Stage 2, and combined results for the 21 SNPs promoted to Stage 2 study along with 
the number of studies and samples contributing to the analysis are presented in Table 2. In total, five 
of the 21 SNPs had significant allelic ORs (95%CIs) in the overall dataset:  FABP1, 0.92 (0.85-0.99); 
CXCL3, 1.16 (1.05-1.29); IL6, 1.08 (1.00-1.17); MSR1, 0.90 (0.82-0.98); and MMP9, 0.91 (0.87-0.97). 
The directions of association in the discovery and replication samples were consistent for all five 
SNPs. Of these SNPs, only the polymorphisms near CXCL3 and in MMP9 were significantly 
associated with endometrial cancer risk in the replication stage. No heterogeneity across studies was 
found for these five SNPs. 
Table 3 presents the heterozygous, homozygous, and per allele associations with type 1 
endometrial (endometroid) cancer for the five significant SNPs among all women combined, among 
women of Asian ancestry, and among women of European ancestry. SNP rs3918249 in MMP9 was 
associated with endometrial cancer risk in women of both Asian and European ancestry. Other SNPs 
were not significantly associated with endometrial cancer in European-ancestry women. SNP 
rs10503574 in MSR1 was more significant in Asian-ancestry women than in the overall sample. 
When restricting analyses to women with type 1 endometrial cancer, the results were largely 
unchanged.  
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DISCUSSION 
The link between inflammation and endometrial cancer is supported by a great deal of 
experimental and epidemiological evidence, indicating that conditions related to chronic inflammation, 
such as prolonged menstruation, obesity, unopposed menopausal estrogen use, and other factors, 
tend to increase the risk of endometrial cancer (14, 15). Menstruation itself, during which the 
endometrium goes through proliferative, secretory, and menstrual phases, mimics an inflammatory 
process and is associated with the activation of inflammatory cytokines that results in the shedding of 
the endometrium (15). Estrogen directly regulates the production of a number of inflammatory 
cytokines, growth factors, and corresponding receptors (16). Women who have more children or take 
oral contraceptives have relatively lower levels of exposure to estrogen and are at comparatively 
reduced risk of endometrial cancer (17). Increased mitotic activity in endometrial epithelial cells 
results in increased DNA replication and repair errors; these, in turn, can lead to somatic mutations 
that may ultimately give rise to hyperplasia and endometrial cancer (7). 
 In this large two-stage study, including samples from both Asian- and European-ancestry 
populations, we found that genetic variants in five candidate genes, FABP1, CXCL3, IL6, MSR1, and 
MMP9, were associated with endometrial cancer in combined analyses. Of these, only the CXCL3 
and MMP9 polymorphisms had significant associations in the stage 2 analysis. Only rs3918249, the 
MMP9 variant, was associated with endometrial cancer in both Asian- and European-ancestry 
samples.  
MMP9 encodes a matrix metalloproteinase, involved in the breakdown of the extracellular 
matrix, a process which has been well studied for its relationship with cancer. MMP9 is secreted from 
endometrial stromal cells in response to induction by growth factors, such as HGF, in endometrial 
cancer cell lines, which, in turn, increases cancer cell invasiveness (18). Expression of MMP9 is 
known to be up-regulated through pro-inflammatory cytokines, including nuclear factor kappa B, IL8, 
and TNF-alpha, leading to increased tumor cell proliferation (19-21). MMP9 expression level has 
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been correlated to the grade and stage of endometrial cancer (22). The MMP9 protein has been 
shown to be frequently expressed in endometriosis, a benign disease, in which MMP9 expression 
level is higher in aggressive lesions than in normal endometrium (23, 24). MMP9 transgenic mice 
show significantly increased susceptibility to chemically induced cancer (25). The significant SNP we 
found, rs3918249, resides in a promoter region of MMP9, and is predicted to be in a transcription 
factor binding site. Further, it is in linkage disequilibrium with a non-synonymous coding SNP, 
rs17576, in MMP9, though this is predicted to be benign by PolyPhen-2 and SIFT (26, 27). Further 
investigation of the role of this gene in endometrial carcinogenesis is warranted.  
SNP rs352038 near the CXCL3 gene was our second most significant finding overall and, like 
MMP9, independently significant in the replication sample. CXCL3 is an attractive candidate gene, 
although rs352038 is not located in the CXCL3 gene, but 14.2kb downstream. However, it is in 
linkage disequilibrium with SNPs in other CXC chemokine genes in the 4q21 region, including CXCL2 
and CXCL5. CXCL3 is upregulated in breast cancer, is present at higher levels in metastases, and is 
associated with shorter relapse-free survival in patients treated with tamoxifen (28). Consistent with 
the hormonal etiology of endometrial cancer, gonadotropin releasing hormone (GnRH) I and II may 
regulate the expression of CXCL3 (29). CXCL3 has shown to be up-regulated in uterine smooth 
muscle. Inhibition of CXCL3 and IL6 has been shown in cancer cell lines to reduce Stat3 activation 
(30). It is worth noting that the genotyped SNP rs352038 is predicted to act as an eQTL for another 
inflammatory gene, IL8 (P = 0.007), though this gene is over 300kb distant from rs352038 (31).  
Three other SNPs in or near FABP1 (rs2970294), IL6 (rs2069852), and MSR1 (rs10503574) 
with significant associations in stage 1 data were also significant in the overall dataset, although they 
were not replicated in stage 2. The FABP1 gene is a four exon gene on chromosome 2p11.2, which is 
involved in binding fatty acids and the regulation of lipid transport and metabolism. The FABP1 
protein is a target for tamoxifen binding, but its expression is predominantly in the liver, colon, and 
small intestine (32). High serum levels of IL6  have been found in endometrial carcinoma, including 
carcinomas with serous histology (33). IL6 appears to increase expression of MMP9 protein levels 
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(34, 35). The MSR1 gene is an 80kb, 11-exon gene on chromosome 8 encoding a macrophage 
scavenger receptor. Polymorphisms in this gene may play a role in the prostate cancer of Chinese 
and European-ancestry men (36-38). While this association was not replicated in stage 2 data, the 
signal was more significant in the overall Asian dataset than in stage 1 (OR (95%CI): 0.826 (0.738-
0.925)).  
The present study has a number of strengths and weaknesses. The study benefits from its 
collection of a relatively large number of case and control samples from a number of study sites. The 
increased sample size and consistent directions of association across a number of study sites 
strengthens the evidence that these findings—particularly for the CXCL3 and MMP9 SNPs—are 
much more likely to represent true associations. Limitations include that stage 1 was carried out in an 
Asian population, and only one SNP per region was selected for the replication study. Some 
association findings may not extend to non-Asian populations, because of linkage disequilibrium 
structure differences resulting in false negative results, as may be the case for rs10503574 in MSR1, 
where linkage disequilibrium blocks as defined by D-prime are quite different between HapMap 
samples for CEU and CHB+JPT. Minor allele frequencies in European populations were also quite 
low (Table 3) for three of the five SNPs significant overall, resulting in reduced power to detect 
associations for CXCL3, IL6, and MSR1. Another limitation is that this analysis was restricted to 
SNPs in or near (within 20kb) the 64 candidate inflammation genes. Future studies may wish to 
expand investigations to SNPs known to be eQTLs for inflammatory genes, some of which may be 
more distant or even in trans to the genes they regulate. Such variations may offer more potent 
explanations of the expression levels of inflammatory genes. As new resources such as the The 
Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression project (GTEx) are developed, the 
tools to determine the SNPs controlling the expression of these genes in relevant tissue types will 
allow more specific tests to be carried out.  
In summary, this study found evidence for the involvement of MMP9 and CXCL3 in 
endometrial carcinogenesis in both Asian- and European-ancestry populations. These findings may 
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warrant additional and functional studies to determine the mechanisms by which these common 
variants increase disease risk. Future studies may focus on specific eQTL SNPs in the tissues of 
interest and seek to better explore the link between these inflammatory pathway genes and 
endometrial carcinogenesis. 
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Table 1. Study populations included. 
 
Study Abbreviation General Setting Cases Controls Genotyping platform 
Stage 1 Sample Sets Stage 1         
Shanghai Endometrial 
Cancer Genetic Study SECGS-I 
Shanghai, China; 
Population-based, 
case-control studies 
832 2,682 Affymetrix 6.0 
            
Stage2 Sample Sets Stage 2         
Australian National 
Endometrial Cancer 
Study/Newcastle 
Endometrial Cancer 
Study 
ANECS/NECS 
Australia; Population-
based, case-control 
study/Hospital-based 
study 
1,436 1,175 Sequenom 
Bavarian Endometrial 
Cancer Study BECS 
Germany; Population-
based, case-control 
study 
202 387 Sequenom 
Connecticut Endometrial 
Cancer Study  CECS 
Connecticut, USA; 
Population-based, 
case-control study 
534 621 Sequenom 
Hannover-Almaty 
Endometrial Cancer 
Study  
HAECS 
Kazakhstan; Hospital-
based, case-control 
study 
218 232 Taqman 
Hawaii Endometrial 
Cancer Study  HECS 
Hawaii, USA; 
Population-based, 
case-control study 
168 574 Sequenom 
Hannover-Jena 
Endometrial Cancer 
Study 
HJECS 
Germany; Hospital-
based, case-control 
study 
229 554 Taqman 
Leuven Endometrial 
Cancer Study LES 
Belgium; Hospital-
based, case-control 
study 
264 591 Sequenom 
Molecular Markers in 
Treatment of 
Endometrial Cancer 
MoMaTEC 
Norway; Population-
based, case-control 
study 
411 210 Sequenom 
National Study of the 
Genetics of Endometrial 
Cancer 
NSECG 
United Kingdom; 
Population-based, 
case-control study 
1,514 507 
Illumina 
550K / 
Sequenom 
Shanghai Endometrial 
Cancer Genetic Study SECGS-II 
Shanghai, China; 
Population-based, 
case-control studies 
796 978 Sequenom 
Total     6,604 8,511   
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Table 2. Associations with endometrial cancer for the 21 SNPs included in each stage and overall. 
    Study Stage 
Discovery Replication Overall 
rsID Reference allelea 
Adjacent 
Genes  OR (95% CI)
b Pc  Studies
d OR (95%CI)e Pf  
OR meta 
(95%CI)g P 
h Heterogeneity P-value 
rs2780815 G JAK1 0.74 (0.63-0.88) 3.72E-04 8 0.98(0.92-1.04) 0.471 0.94(0.86-1.03) i 0.193 0.032 
rs310247 A JAK1 0.81 (0.71-0.91) 0.001 8  0.99(0.90-1.08) i 0.769 0.96(0.88-1.06) i 0.412 0.006 
rs12757165 G ESRRG 0.78 (0.68-0.89) 2.49E-04 8 0.99(0.93-1.05) 0.638 0.95(0.87-1.04) i 0.299 0.023 
rs17627111 G ESRRG 0.72 (0.62-0.85) 4.93E-05 8 0.99(0.93-1.05) 0.782 0.98(0.89-1.08) i 0.681 0.010 
rs2970924 T FABP1 0.80 (0.68-0.96) 0.013 7 0.95(0.87-1.03) 0.214 0.92(0.85-0.99) 0.024 0.244 
rs9839934 G THRB 0.80 (0.69-0.94) 0.006 8 1.00(0.94-1.07) 0.951 0.97(0.91-1.02) 0.253 0.282 
rs1472095 T PPARGC1A 1.41 (1.13-1.77) 0.003 8  1.09(0.97-1.24) i 0.152 1.13(1.00-1.28) i 0.054 0.006 
rs352038 G CXCL3 1.26 (1.06-1.50) 0.008 10 1.14(1.00-1.29) 0.050 1.16(1.05-1.29) 0.003 0.498 
rs2735188 C HDAC3 1.38 (1.09-1.75) 0.007 8 1.00(0.90-1.10) 0.939 1.05(0.96-1.14) 0.311 0.099 
rs1421894 T CENTD3 0.86 (0.75-0.98) 0.028 8 1.04(0.97-1.12) 0.225 0.98(0.89-1.09) i 0.767 0.021 
rs7709864 C LOC729123 1.25 (1.07-1.46) 0.006 8  1.20(0.94-1.52) i 0.137 1.17(0.98-1.41) i 0.084 0.001 
rs6914211 A ESR1 1.40 (1.15-1.70) 0.001 8 0.99(0.90-1.09) 0.905 1.05(0.97-1.15) 0.237 0.341 
rs2069852 A IL6 1.19 (1.04-1.36) 0.013 7 1.05(0.96-1.16) 0.284 1.08(1.00-1.17) 0.049 0.154 
rs933360 C GRB10 0.75 (0.65-0.87) 8.40E-05 8 1.02(0.96-1.09) 0.542 0.97(0.91-1.03) 0.269 0.067 
rs10503574 C MSR1 0.81 (0.70-0.94) 0.006 6 0.97(0.86-1.08) 0.547 0.90(0.82-0.98) 0.016 0.088 
rs4149319 A ABCA1 0.76 (0.63-0.91) 0.003 8 0.99(0.87-1.13) 0.937 0.91(0.82-1.01) 0.074 0.194 
rs3781619 A DDB2 1.18 (1.04-1.35) 0.013 8 0.93(0.87-1.00) 0.062 0.96(0.87-1.06) i 0.457 0.041 
rs12368672 G STAT6 1.32 (1.15-1.53) 1.05E-04 8 1.00(0.94-1.06) 0.987 1.04(0.99-1.10) 0.139 0.096 
rs2239349 A IL4R 1.17 (1.00-1.36) 0.046 8  1.14(0.92-1.40) i 0.235 1.13(0.96-1.34) i 0.150 0.001 
rs9896401 C SAMD14 1.43 (1.14-1.80) 0.002 8 0.96(0.90-1.03) 0.286 1.00(0.93-1.07) 0.944 0.061 
rs3918249 C MMP9 0.81 (0.70-0.92) 0.002 10 0.94(0.88-1.00) 0.042 0.91(0.87-0.97) 0.001 0.153 
a Allele associated with the ORs specified in the table. 
b OR in discovery stage of inflammation study. 
c P-value for discovery stage (SECGS-I data) 
d Number of studies contributing data to replication stage. 
e OR meta based on some or all of the following studies ANECS, BECS, CECS, HAECS, HECS, HJECS, LES, MoMaTEC, NSECG, and SECGS-II. 
f Meta-analysis P-value for replication stage including ANECS, BECS, CECS, HAECS, HECS, HJECS, LES, MoMaTEC, NSECG, and SECGS-II 
g OR for all studies combined. 
h P-value for overall meta-analysis including replication and discovery stages. 
i Random effects model used 
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Table 3. Association with endometrial cancer risk for selected variants by ethnicity and histological type. 
Population 
SNP 
N   Allele Freq   OR (95% CI) 
P 
Cases Controls   Cases  Controls   Heterozygous Homozygous Allelic 
All women, endometrial cancer cases vs. controls             
  rs2970924 5832 7037   0.15 0.16    0.90(0.82-0.98) 0.93(0.72-1.20)  0.92(0.85-0.99) 0.024 
  rs352038 6568 8405   0.06 0.08    1.16(1.03-1.30) 1.30(0.90-1.86)  1.16(1.05-1.29) 0.003 
  rs2069852 5784 6922   0.21 0.38    0.98(0.86-1.13) 1.08(0.90-1.29)  1.08(1.00-1.17) 0.049 
  rs10503574 3026 6685   0.16 0.17    0.93(0.84-1.04) 0.76(0.59-0.98)  0.90(0.82-0.98) 0.016 
  rs3918249 6561 8273   0.44 0.53    0.95(0.87-1.04) 0.83(0.73-0.93)  0.91(0.87-0.97) 0.001 
                        
All Asian-ancestry endometrial cancer cases vs. controls       
  rs2970924 1714 3783   0.15 0.16     0.87(0.70-1.08)  0.77(0.48-1.25)  0.82(0.63-1.07) 0.140 a 
  rs352038 1693 3773   0.17 0.16    1.11(0.98-1.27)   1.28(0.88-1.88)  1.12(1.00-1.26) 0.047 
  rs2069852 1635 3675   0.66 0.65    0.91(0.75-1.11)   1.07(0.88-1.30)  1.08(0.99-1.18) 0.101 
  rs10503574 1685 3823   0.24 0.26    0.89(0.79-1.01)   0.70(0.54-0.91)  0.86(0.78-0.95) 0.003 
  rs3918249 1700 3654   0.70 0.72    0.91(0.73-1.13)   0.78(0.63-0.98)  0.88(0.80-0.97) 0.008 
                
All European-ancestry endometrial cancer cases vs. 
controls      
  rs2970924 3856 2856   0.16 0.15    0.89(0.79-1.00)  1.07(0.77-1.50)   0.94(0.84-1.04) 0.206 
  rs352038 4553 4111   0.02 0.01    1.16(0.87-1.54)  1.23(0.99-1.54)   1.18(0.89-1.57) 0.250 
  rs2069852 3889 2850   0.03 0.03    1.00(0.80-1.26)  0.31(0.06-1.49)   1.00(0.80-1.25) 0.997 
  rs10503574 1214 2450   0.05 0.04    1.10(0.82-1.49)  0.31(0.06-1.49)   1.07(0.80-1.43) 0.653 
  rs3918249 4539 4098   0.35 0.36    0.97(0.87-1.08)  0.82(0.70-0.96)   0.92(0.86-0.99) 0.024 
                
All women, type I endometrial cancer cases vs. controls 
  rs2970924 4703 7037   0.15 0.16    0.89(0.81-0.98)  0.94(0.72-1.22)  0.91(0.84-0.99) 0.027 
  rs352038 5285 8405 0.06 0.08  1.17(1.03-1.32)  1.28(0.87-1.88)  1.17(1.05-1.30) 0.004 
  rs2069852 4653 6922 0.22 0.38  0.98(0.85-1.13)  1.08(0.89-1.31)  1.10(1.01-1.19) 0.030 
  rs10503574 2605 6685 0.16 0.17  0.93(0.83-1.04)  0.70(0.53-0.92)  0.88(0.80-0.96) 0.007 
  rs3918249 5484 8273 0.45 0.53  0.97(0.88-1.07)  0.82(0.72-0.93)  0.91(0.86-0.97) 0.002 
    
Asian-ancestry women, type I endometrial cancer cases vs. controls 
  rs2970924 1464 3783 0.15 0.16 0.90(0.78-1.04)  0.79(0.52-1.20)  0.89(0.79-1.00) 0.055 
  rs352038 1448 3773 0.17 0.16 1.14(0.99-1.31)  1.24(0.83-1.87)  1.13(1.00-1.28) 0.041 
  rs2069852 1393 3675 0.67 0.65 0.88(0.71-1.07)  1.07(0.88-1.32)  1.09(0.99-1.20) 0.075 
  rs10503574 1439 3823 0.23 0.26 0.88(0.78-1.01)  0.68(0.51-0.90)  0.85(0.77-0.94) 0.002 
  rs3918249 1453 3654 0.70 0.72 0.93(0.74-1.18)  0.80(0.63-1.01)  0.89(0.80-0.98) 0.015 
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European-ancestry women, type I endometrial cancer cases vs. controls   
  rs2970924 3037 2856   0.15 0.15  0.86(0.76-0.98)  1.05(0.74-1.49)  0.91(0.82-1.02) 0.099 
  rs352038 3580 4111   0.02 0.01  1.16(0.86-1.57)  1.26(1.00-1.59)  1.19(0.88-1.60) 0.255 
  rs2069852 3060 2850   0.03 0.03 1.07(0.72-1.60)  0.54(0.05-5.40)  1.08(0.72-1.62) 0.703 a 
  rs10503574 1061 2450 0.05 0.04  1.12(0.82-1.53)  0.54(0.05-5.40)  1.07(0.80-1.45) 0.644 
  rs3918249 3574 4098   0.35 0.36    0.98(0.88-1.10)  0.79(0.67-0.93)  0.91(0.84-0.98) 0.017 
                        
a Random effects model used             
 23
 
Figure Legends 
 
Figure 1. Selection and prioritization of inflammation-related SNPs for meta-analysis. 
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Figure 1 
 
  
 
Identify B36 genomic coordinates ± 20kb flanking each gene for 64 
inflammation candidate genes. Evaluate 4,542 common SNPs for 
associations with endometrial cancer in the SECGS 
614 SNPs identified as significantly associated with endometrial 
cancer were grouped into 24 distinct loci (r
2 
> 0.3) 
Peak P-values for each locus determined the SNP selected, unless it 
could not be designed, in which case alternate SNPs were selected 
leaving a total of 24 SNPs 
21 SNPs were successfully designed, genotyped, and passed QC 
Some or all of the SNPs were genotyped for stage 2 by 
ANECS/NECS, BECS, CECS, HAECS, HECS, HJECS, LES, MoMaTEC, 
NSECG, and additional samples from the SECGS
Stage 2 and overall meta-analysis P-values were computed 
